Table 3.
Associations between the number of unfavorable genotypes of three independent SNPs with NSCLC OS and DSS in the PLCO Trial
| Genotype | Frequencya | OSb |
DSSb |
||||
|---|---|---|---|---|---|---|---|
| Death (%) | HR (95% CI) | P | Death (%) | HR (95% CI) | P | ||
| CHEK1 rs76744140 T>C | |||||||
| TT | 1018 | 664 (65.23) | 1.00 | -- | 595 (58.45) | 1.00 | -- |
| TC | 152 | 120 (78.95) | 1.21 (0.99–1.47) | 0.0622 | 109 (71.71) | 1.20 (0.98–1.48) | 0.0835 |
| CC | 5 | 5 (100.00) | 4.44 (1.81–10.90) | 0.0011 | 5 (100.00) | 4.50 (1.83–11.05) | 0.0011 |
| Trend test | 0.0101 | 0.0133 | |||||
| Dominant | |||||||
| TT | 1018 | 664 (65.23) | 1.00 | -- | 595 (58.45) | 1.00 | -- |
| TC+CC | 157 | 125 (79.62) | 1.25 (1.03–1.52) | 0.0267 | 114 (72.61) | 1.25 (1.02–1.53) | 0.0357 |
| PRIM2 rs6939623 G>T | |||||||
| GG | 973 | 635 (65.26) | 1.00 | -- | 575 (59.10) | 1.00 | -- |
| GT | 197 | 150 (76.14) | 1.43 (1.19–1.71) | 0.0001 | 132 (67.01) | 1.40 (1.16–1.70) | 0.0006 |
| TT | 5 | 4 (80.00) | 0.88 (0.33–2.38) | 0.7992 | 2 (40.00) | 0.46 (0.11–1.85) | 0.2712 |
| Trend test | 0.0006 | 0.0072 | |||||
| Dominant | |||||||
| GG | 973 | 635 (65.26) | 1.00 | -- | 575 (59.10) | 1.00 | -- |
| GT+TT | 202 | 154 (76.24) | 1.41 (1.17–1.68) | 0.0002 | 134 (66.34) | 1.36 (1.12–1.64) | 0.0017 |
| CDK6 rs113181986 G>C | |||||||
| GG | 1044 | 710 (68.01) | 1.00 | -- | 637 (61.02) | 1.00 | -- |
| GC | 129 | 78 (60.47) | 0.75 (0.59–0.95) | 0.0175 | 71 (55.04) | 0.79 (0.61–1.01) | 0.0630 |
| CC | 2 | 1 (50.00) | 0.56 (0.08–4.02) | 0.5663 | 1 (50.00) | 0.62 (0.09–4.45) | 0.6353 |
| Trend test | 0.0146 | 0.0554 | |||||
| Dominant | |||||||
| GG | 1044 | 710 (68.01) | 1.00 | -- | 637 (61.02) | 1.00 | -- |
| GC+CC | 131 | 79 (60.31) | 0.74 (0.58–0.94) | 0.0150 | 72 (54.96) | 0.78 (0.61–1.01) | 0.0568 |
| Reserved | |||||||
| GC+CC | 131 | 79 (60.31) | 1.00 | 72 (54.96) | 1.00 | -- | |
| GG | 1044 | 710 (68.01) | 1.35 (1.06–1.71) | 0.0150 | 637 (61.02) | 1.28 (0.99–1.64) | 0.0568 |
| NUG c | |||||||
| 0 | 98 | 54 (55.10) | 1.00 | -- | 50 (51.02) | 1.00 | -- |
| 1 | 774 | 503 (64.99) | 1.36 (1.03–1.81) | 0.0332 | 453 (58.53) | 1.28 (0.95–1.72) | 0.1012 |
| 2 | 280 | 210 (75.00) | 1.79 (1.32–2.42) | 0.0002 | 186 (66.43) | 1.65 (1.20–2.26) | 0.0021 |
| 3 | 23 | 22 (95.65) | 2.41 (1.45–4.00) | 0.0007 | 20 (86.96) | 2.21 (1.30–3.75) | 0.0034 |
| Trend test | <0.0001 | <0.0001 | |||||
| Dichotomized NUG | |||||||
| 0–1 | 872 | 557 (63.88) | 1.00 | -- | 503 (57.68) | 1.00 | -- |
| 2–3 | 303 | 232 (76.57) | 1.39 (1.19–1.62) | <0.0001 | 206 (67.99) | 1.35 (1.15–1.60) | 0.0003 |
Abbreviations: SNP, single nucleotide polymorphism; NSCLC, non-small cell lung cancer; OS, overall survival; DSS, disease-specific survival. PLCO, Prostate, Lung, Colorectal and Ovarian cancer screening trial; HR, hazards ratio; CI, confidence interval; NUG, number of unfavorable genotypes.
a
10 with missing data were excluded.
b
Adjusted for age, sex, smoking status, histology, tumor stage, chemotherapy, surgery, radiotherapy and principal components.
c
Unfavorable genotypes were CHEK1 rs76744140_TC+CC, PRIM2 rs6939623_GT+TT, and CDK6 rs113181986 GG.